Table 3.
JUPITER trial: comparison of outcomes between treated and nontreated patients
| End point | Patients in subgroup rosuvastatin (n = 8901) | Patients in subgroup placebo (n = 8901) | Hazard ratio (95% CI) |
|---|---|---|---|
| Primary end pointa | 142 | 251 | 0.56 (0.46–0.69) |
| Any MI | 31 | 68 | 0.46 (0.30–0.70) |
| Nonfatal MI | 22 | 62 | 0.35 (0.22–0.58) |
| Any stroke | 33 | 64 | 0.52 (0.34–0.79) |
| Nonfatal stroke | 30 | 58 | 0.52 (0.33–0.80) |
| Revascularization | 71 | 131 | 0.54 (0.41–0.72) |
| Hospitalization for unstable angina | 16 | 27 | 0.59 (0.32–1.10) |
| Revascularization or hospitalization for unstable angina | 76 | 143 | 0.53 (0.40–0.70) |
| MI, stroke, or death from cardiovascular causes | 83 | 157 | 0.53 (0.40–0.69) |
| Any death | 198 | 247 | 0.80 (0.67–0.97) |
a
Notes: Primary end point: composite of nonfatal MI, nonfatal stroke, hospitalization for unstable angina, revascularization, and death from cardiovascular causes.
Abbreviations: CI, confidence interval; MI, myocardial infarction.